Norwalk Leslie V 4
4 · NEUROCRINE BIOSCIENCES INC · Filed May 14, 2026
Research Summary
AI-generated summary of this filing
Neurocrine (NBIX) Director Leslie V. Norwalk Sells 3,810 Shares
What Happened Leslie V. Norwalk, a director of Neurocrine Biosciences (NBIX), sold 3,810 shares in open-market transactions on May 12, 2026. The weighted-average sales price was $155.01 per share, for total proceeds of approximately $590,601. This was a sale (not a purchase), and the filing indicates the trades were executed under a pre-established 10b5‑1 trading plan.
Key Details
- Transaction date: May 12, 2026 (Form 4 filed May 14, 2026) — filing appears timely (filed within two business days).
- Transaction type/code: Sale (S).
- Shares sold: 3,810; weighted-average price: $155.01; total value: ~$590,601.
- Price range: shares sold in multiple trades at $155.00 to $155.0550 (report includes a footnote offering per-price breakdown on request).
- Shares owned after transaction: Not specified in the provided Form 4.
- Footnotes: F1 — disposition executed by broker under a 10b5‑1 plan adopted September 15, 2025; issuer policy prevents amending the plan after adoption. F2 — weighted-average price noted; detailed per-trade breakdown available upon request.
Context Sales made under a 10b5‑1 plan are generally pre-planned and routine rather than an immediate signal of insider sentiment. This report documents a straightforward open-market sale by a director; no derivatives, option exercises, gifts, or tax-withholding events were reported in the disclosed transaction.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-05-12$155.01/sh−3,810$590,601→ 2,429 total
Footnotes (2)
- [F1]The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted and effective on September 15, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- [F2]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $155.00 to $155.0550. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.